Diabetes Obes Metab: Liraglutide treatment for overweight and obese type 1 diabetes patients

Previous studies have shown that adding liraglutide to insulin in patients with type 1 diabetes (T1DM) for 12 weeks improves blood sugar control, reduces weight and reduces systolic blood pressure (SBP)In a recent study published in the journal Diabetes Obesity and Metabolism, the leading journal for metabolic endocrine diseases, researchers aimed to assess the effects of liraglutide therapy on blood sugar control and fat tissue metabolism in overweight and obese T1DM patientsresearchers randomized 84 adult overweight and obese TIDM patients who did not detect c peptides to a placebo or 1.8 mg/day of liraglutide therapy for a period of 6 monthsBlood samples from subjects were collected at weeks 0, 12 and 26Subcutaneous adipose tissue biopsies, high-calorie, high-fat (HCHF) meals, CGM, DEXA, and MRI tests were performed before and after treatment37 patients in the study and 27 patients in the treatment group treated with liraglutide or placebo, respectivelyAfter liraglutide treatment, HbA1c decreased by 0.41 to 0.18% compared to the baseline (p-0.001), and after placebo treatment, it decreased by 0.29 to 0.19% (p-0.1)The low blood sugar event did not increase, but the time spent on normal blood sugar increased (p.015), while the time spent on high blood sugar decreased (p.019)The significant weight loss of liraglutide after treatment was mainly characterized by a decrease in fat (including visceral fat) while lean meat did not changeAfter liraglutide treatment, SBP also declinedLiraglutide therapy can also significantly increase the expression of ATGL, CPT-1, PPAR alpha, PPAR, UCP-2, and Dio-2 in adipose tissue, liraglutide improves blood sugar, reduces obesity and SBPLiraglutide also stimulates lipid oxidation and increased heat production while maintaining lean weight